These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 7905660)

  • 1. Effects of ebrotidine on aspirin-induced gastric mucosal damage and blood flow in humans.
    Konturek SJ; Kwiecien N; Sito E; Obtulowicz W; Kaminski K; Oleksy J
    Scand J Gastroenterol; 1993 Dec; 28(12):1047-50. PubMed ID: 7905660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies on the cytoprotective and antisecretory activity of ebrotidine. A review.
    Konturek PC; Brzozowski T; Konturek SI; Márquez M; Torres J; Ortiz JA
    Arzneimittelforschung; 1997 Apr; 47(4A):578-89. PubMed ID: 9205769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastroprotective properties of ebrotidine. A review.
    Slomiany BL; Piotrowski J; Slomiany A
    Arzneimittelforschung; 1997 Apr; 47(4A):459-67. PubMed ID: 9205744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies on the protective effect of ebrotidine on experimental ulcers induced by non-steroidal anti-inflammatory drugs in healthy volunteers.
    Puscas I; Puscas C; Coltau M; Torres J; Márquez M; Herrero E; Fillat O; Ortiz JA
    Arzneimittelforschung; 1997 Apr; 47(4A):565-8. PubMed ID: 9205766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of tumor necrosis factor-alpha and apoptosis in gastric mucosal injury by indomethacin: effect of omeprazole and ebrotidine.
    Slomiany BL; Piotrowski J; Slomiany A
    Scand J Gastroenterol; 1997 Jul; 32(7):638-42. PubMed ID: 9246701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ebrotidine--a new H2-receptor antagonist with mucosal strengthening activity.
    Piotrowski J; Yamaki K; Morita M; Slomiany A; Slomiany BL
    Biochem Int; 1992 Mar; 26(4):659-67. PubMed ID: 1351724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastroprotective and ulcer-healing activities of a new H2-receptor antagonist: ebrotidine.
    Brzozowski T; Majka J; Konturek SJ
    Digestion; 1992; 51(1):27-36. PubMed ID: 1353465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ebrotidine.
    Patel SS; Wilde MI
    Drugs; 1996 Jun; 51(6):974-80; discussion 981. PubMed ID: 8736619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastric acid inhibitory profile of ebrotidine, a novel H2-receptor antagonist in humans.
    Maczka M; Kwiecień N; Obtułowicz W; Konturek SJ; Kamiński K; Oleksy J; Gabryelewicz A; Torres J
    J Physiol Pharmacol; 1992 Jun; 43(2):139-48. PubMed ID: 1356519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of gastric mucosal calcium channel activity by an antiulcer agent, ebrotidine.
    Slomiany BL; Liu J; Piotrowski J; Czajkowski A; Yotsumoto F; Slomiany A
    J Physiol Pharmacol; 1994 Mar; 45(1):121-31. PubMed ID: 7519082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gastroprotective and antisecretory effects of ebrotidine.
    Konturek SJ; Maczka J; Kaminski K; Sito E; Torres J; Oleksy J
    Scand J Gastroenterol; 1992 Jun; 27(6):438-42. PubMed ID: 1352908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of ebrotidine on ethanol-induced gastric mucosal damage in the rat. Comparative study with other H2-receptor antagonists.
    Palop D; Romero A; Villamayor F; Conejo L; Sacristán A; Ortiz JA
    Arzneimittelforschung; 1997 Apr; 47(4A):450-4. PubMed ID: 9205742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of ebrotidine on gastric mucosal inflammatory responses to Helicobacter pylori lipopolysaccharide.
    Slomiany BL; Piotrowski J; Slomiany A
    J Physiol Pharmacol; 1999 Sep; 50(3):391-404. PubMed ID: 10574469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of ebrotidine protection against gastric mucosal injury induced by ethanol.
    Slomiany BL; Piotrowski J; Murty VL; Slomiany A
    Gen Pharmacol; 1992 Jul; 23(4):719-27. PubMed ID: 1356875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of ebrotidine on gastric mucosal calcium channel activity.
    Slomiany BL; Liu J; Kawai T; Czajkowski A; Slomiany A
    Am J Gastroenterol; 1993 Jun; 88(6):881-6. PubMed ID: 8099251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastric mucosal blood flow and neutrophil activation in aspirin-induced gastric mucosal damage in man.
    Konturek JW; Dembinski A; Stoll R; Konturek M; Domschke W
    Scand J Gastroenterol; 1993 Sep; 28(9):767-71. PubMed ID: 8235431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-Helicobacter pylori activities of ebrotidine. A review of biochemical and animal experimental studies and data.
    Slomiany BL; Piotrowski J; Slomiany A
    Arzneimittelforschung; 1997 Apr; 47(4A):475-82. PubMed ID: 9205747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double-blind crossover study of ranitidine and ebrotidine in gastro-esophageal reflux disease.
    Sito E; Thor PJ; M[aczka M; Lorens K; Konturek SJ; Maj A
    J Physiol Pharmacol; 1993 Sep; 44(3):259-72. PubMed ID: 8241527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastric mucosal EGF and PDGF receptor expression with ulcer healing by ebrotidine.
    Slomiany BL; Piotrowski J; Czajkowski A; Yotsumoto F; Slomiany A
    Am J Gastroenterol; 1994 Jun; 89(6):894-7. PubMed ID: 8198101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of endogenous nitric oxide and sulfhydryl compounds in ebrotidine-induced gastroprotection.
    Palop D; Conejo L; Sacristán A; Ortiz JA
    Arzneimittelforschung; 1997 Apr; 47(4A):468-71. PubMed ID: 9205745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.